BiotechTube

methotrexate + methotrexate - etanercept - prednisolone arm

ApprovedCompleted
0 views this week 0 watching⚡ Active
Interest: 43/100
43
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Juvenile Chronic Polyarthritis

Conditions

Juvenile Chronic Polyarthritis, Juvenile Idiopathic Arthritis, Juvenile Rheumatoid Arthritis

Trial Timeline

May 1, 2007 → Oct 1, 2010

NCT ID
NCT00443430

About methotrexate + methotrexate - etanercept - prednisolone arm

methotrexate + methotrexate - etanercept - prednisolone arm is a approved stage product being developed by Amgen for Juvenile Chronic Polyarthritis. The current trial status is completed. This product is registered under clinical trial identifier NCT00443430. Target conditions include Juvenile Chronic Polyarthritis, Juvenile Idiopathic Arthritis, Juvenile Rheumatoid Arthritis.

What happened to similar drugs?

0 of 20 similar drugs in Juvenile Chronic Polyarthritis were approved

Approved (0) Terminated (2) Active (18)
🔄PLX-200 + PlaceboPolaryx TherapeuticsPhase 3
🔄MRA(Tocilizumab)Chugai PharmaceuticalPhase 3
🔄MRA(Tocilizumab) + placeboChugai PharmaceuticalPhase 3
🔄MRA(Tocilizumab)Chugai PharmaceuticalPhase 3
🔄MRA(Tocilizumab)Chugai PharmaceuticalPhase 3
🔄AdalimumabEisaiPhase 3
🔄AbataceptOno PharmaceuticalPhase 3

Hype Score Breakdown

Clinical
20
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT00443430ApprovedCompleted

Competing Products

20 competing products in Juvenile Chronic Polyarthritis

See all competitors
ProductCompanyStageHype Score
PLX-200 + PlaceboPolaryx TherapeuticsPhase 3
37
MRA(Tocilizumab)Chugai PharmaceuticalPhase 3
40
MRA(Tocilizumab) + placeboChugai PharmaceuticalPhase 3
40
MRA(Tocilizumab)Chugai PharmaceuticalPhase 3
40
MRA(Tocilizumab)Chugai PharmaceuticalPhase 3
40
AdalimumabEisaiPhase 3
40
AbataceptOno PharmaceuticalPhase 3
40
Ixekizumab + AdalimumabEli LillyPhase 3
44
Baricitinib + PlaceboEli LillyPhase 3
40
BaricitinibEli LillyPhase 3
47
Baricitinib + TocilizumabEli LillyPhase 3
47
adalimumab + MethotrexateAbbViePre-clinical
26
UpadacitinibAbbViePhase 1
33
Upadacitinib + TocilizumabAbbViePhase 3
47
Adalimumab + RisankizumabAbbViePhase 3
47
AdalimumabAbbViePhase 3
40
naproxen + esomeprazoleAstraZenecaPhase 1
29
Alendronate (Fosamax)MerckPre-clinical
26
canakinumabNovartisPhase 3
40
SecukinumabNovartisPhase 1
36